Cargando…

Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple negative breast and ovarian carcinomas

Triple negative breast (TNBC) and ovarian carcinomas (OvCas) with BRCA1 promoter methylation (BRCA1meth) respond more poorly to alkylating agents compared to those bearing mutations in BRCA1 and BRCA2 (BRCAmut). This is a conundrum given the biologically equivalent homologous recombination deficienc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menghi, Francesca, Banda, Kalyan, Kumar, Pooja, Straub, Robert, Dobrolecki, Lacey, Rodriguez, Isabel V., Yost, Susan E., Chandok, Harshpreet, Radke, Marc R., Somlo, George, Yuan, Yuan, Lewis, Michael T., Swisher, Elizabeth M., Liu, Edison T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585706/ https://www.ncbi.nlm.nih.gov/pubmed/35857626 http://dx.doi.org/10.1126/scitranslmed.abn1926

Ejemplares similares

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing
por: Wang, Nan, et al.
Publicado: (2020)

The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
por: Caramelo, Olga, et al.
Publicado: (2019)

Mechanism of tandem duplication formation in BRCA1 mutant cells
por: Willis, Nicholas A., et al.
Publicado: (2017)

Role of BRCA Mutations in the Modulation of Response to Platinum Therapy
por: Mylavarapu, Sanghamitra, et al.
Publicado: (2018)

Cell-type-specific epigenomic variations associated with BRCA1 mutation in pre-cancer human breast tissues
por: Hsieh, Yuan-Pang, et al.
Publicado: (2022)

3D patient-derived tumor models to recapitulate pediatric brain tumors In Vitro
por: Tang-Schomer, Min D., et al.
Publicado: (2022)

A Genomic Instability Score in Discriminating Nonequivalent Outcomes of BRCA1/2 Mutations and in Predicting Outcomes of Ovarian Cancer Treated with Platinum-Based Chemotherapy
por: Zhang, Shaojun, et al.
Publicado: (2014)

Immunologically “cold” triple negative breast cancers engraft at a higher rate in patient derived xenografts
por: Petrosyan, Varduhi, et al.
Publicado: (2022)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer
por: Jia, Xiaomeng, et al.
Publicado: (2022)

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer
por: Chen, Yimeng, et al.
Publicado: (2023)

BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer
por: Stefansson, Olafur A., et al.
Publicado: (2012)

Functional genomics of complex cancer genomes
por: Menghi, Francesca, et al.
Publicado: (2022)

Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells
por: Tanei, Tomonori, et al.
Publicado: (2016)

New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes
por: Vergote, I, et al.
Publicado: (2016)

Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis
por: LIU, MIAO, et al.
Publicado: (2013)

Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
por: Lee, Jin Sun, et al.
Publicado: (2020)

Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer
por: Wu, Jiande, et al.
Publicado: (2020)

Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)
por: Puhalla, Shannon L., et al.
Publicado: (2021)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer – an observational cohort study
por: Unni, Sudhir K., et al.
Publicado: (2016)

BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis
por: Salwa, Amreen, et al.
Publicado: (2021)

Breast cancer therapy for BRCA1 carriers: moving towards platinum standard?
por: Imyanitov, Evgeny N
Publicado: (2009)

The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents
por: Kim, Geon, et al.
Publicado: (2019)

Deconvolution of the Genomic and Epigenomic Interaction Landscape of Triple-Negative Breast Cancer
por: Wu, Jiande, et al.
Publicado: (2019)

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
por: Wattenberg, Max M., et al.
Publicado: (2019)

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance
por: Wang, Yifan, et al.
Publicado: (2019)

BRCA2 Mutations and Triple-Negative Breast Cancer
por: Meyer, Peter, et al.
Publicado: (2012)

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
por: Egelston, Colt A., et al.
Publicado: (2023)

Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report
por: Cortesi, Laura, et al.
Publicado: (2022)

Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis
por: Lin, Canling, et al.
Publicado: (2022)

Cellular senescence in progenitor cells contributes to diminished remyelination potential in progressive multiple sclerosis
por: Nicaise, Alexandra M., et al.
Publicado: (2019)

Correction to: In Vivo Modeling of Human Breast Cancer Using Cell Line and Patient-Derived Xenografts
por: Souto, Eric P., et al.
Publicado: (2022)

In Vivo Modeling of Human Breast Cancer Using Cell Line and Patient-Derived Xenografts
por: Souto, Eric P., et al.
Publicado: (2022)

Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis
por: Wang, Chang-Jun, et al.
Publicado: (2020)

BRCA-mutated gastric adenocarcinomas are associated with chromosomal instability and responsiveness to platinum-based chemotherapy
por: Oh, Ji Hyun, et al.
Publicado: (2023)

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
por: Glodzik, Dominik, et al.
Publicado: (2020)

Platinum‐based chemotherapy for early triple‐negative breast cancer
por: Mason, Sofia RE, et al.
Publicado: (2023)

Technical and Regulatory Considerations for Taking Liquid Biopsy to the Clinic: Validation of the JAX PlasmaMonitor(TM) Assay
por: Sisson, Bridgette A, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_me8e18umg22a7iebb7nq73lluh